Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer
The purpose of the study is to assess the clinical effectiveness of Fentanyl ETHYPHARM when used to relieve breakthrough pain (BTP) in opioid-treated cancer patients.
Breakthrough Pain|Cancer
DRUG: Fentanyl Ethypharm
Summed Pain Intensity Difference at 30 minutes (SPID30)., 30 minutes post dose
SPID at 3, 6, 10, 15 and 60 minutes post-dosing, 3, 6, 10, 15 and 60 minutes post-dosing|SPID at 15 and 30 minutes according to the pathophysiology of the pain (neuropathic, nociceptive), 15 and 30 minutes post dose|Pain Intensity Difference at 3, 6, 10, 15, 30 and 60 minutes after dosing, 3, 6, 10, 15, 30 and 60 minutes after dosing|Pain Relief at 3, 6, 10, 15, 30 and 60 minutes after dosing, 3, 6, 10, 15, 30 and 60 minutes after dosing|The proportion of episodes of BTP that required rescue medication, 15 and 30 minutes post dose|the proportion of episodes with more than 33% and 50% of improvement in Pain Intensity scores, 15 and 30 minutes post dose|Recording of safety data, Adverse events, vital signs, urinary pregnancy test, During all the study duration, an expected average of 8 weeks
The purpose of the study is to assess the clinical effectiveness of Fentanyl ETHYPHARM when used to relieve breakthrough pain (BTP) in opioid-treated cancer patients.